source
- AbbVie’s lutikizumab meets primary endpoint in Phase 3 hidradenitis trial but falls short of market expectationsAbbVie announced that its experimental drug lutikizumab achieved its primary goal in a Phase 3 study of hidradenitis suppurativa, a chronic inflammatory skin disease. The Intrepid trial enrolled a…
- Treasury rumored to consider rule limiting U.S. investment in Chinese biotechA report says the U.S. Treasury is expected to propose a regulation that would curb American investment in China’s biotech sector. The story notes the proposal is still a rumor and no formal rule h…